Nurix Therapeutics develops novel therapies that modulate protein levels through small molecule drugs targeting E3 ligases. Nurix's pipeline is focused on developing drugs for immune-mediated diseases and hematologic cancers including immuno-oncology therapeutics. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors and corporate partners. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/17/20 | $120,000,000 | Venture |
Bain Capital Life Sciences Boxer Capital EcoR1 Capital Foresite Capital  Redmile Group The Column Group Third Rock Ventures Wellington Management Company | undisclosed |
